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ABSTRACT: To assess the prevalence of genetic mutations in nonsyn-
dromic pheochromocytoma/paraganglioma (PHEO/PGL) patients we
have performed a systematic search for mutations in the succinate de-
hydrogenase (SDH) B, C, and D subunits, von Hippel–Lindau (VHL),
and RET genes by direct bidirectional sequencing. Patients were selected
from the medical records of hypertension centers. After exclusion of syn-
dromic patients, 45 patients with familial (F+, n = 3) and sporadic (F−,
n = 42) cases of isolated PHEO/PGL were considered. They included 35
patients with PHEO, 7 with PGL, and 3 with head/neck PGL (hnPGL).
Three patients with PHEO (2F−, 1F+) presented VHL mutations (P86A,
G93C, and R167W), six with PGL (4F−, 2F+) were positive for SDH
or VHL mutations (SDHB R230G in two patients, SDHB S8F, R46Q,
R90Q, and VHL P81L in one subject each), and one with hnPGL carried
the SDHD 348–351delGACT mutation. We have also detected missense
(SDHB S163P, SDHD H50R and G12S), synonymous (SDHB A6A, SDHD
S68S), and intronic mutations that have been considered nonpathological
polymorphic variants. No mutation was found in SDHC or RET genes.
Our data indicate that germline mutations of VHL and SDH subunits are
not infrequent in familial as well as in sporadic cases of nonsyndromic
PHEO/PGL (overall, 12 of 45 probands, 22%). Accordingly, screening
for such mutations seems to be justified. However, a more precise char-
acterization of the functional relevance of any observed sequence variant
and of other genetic and environmental determinants of neoplastic trans-
formation is essential in order to plan appropriate protocols for family
screening and follow-up.
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INTRODUCTION
There is considerable variety in the definition of pheochromocytoma
(PHEO) and paraganglioma (PGL). The common denominators are the
embryological origin (a subset of neural crest–derived cells) and the histopatho-
logical appearance, whereas differential features derive from their anatomical
location (adrenal medulla or paraganglia aligned to sympathetic or parasym-
pathetic nervous system) and from the ability of producing catecholamine
and various neuropeptides. The definition of PHEO should be reserved
for catecholamine-producing tumors originating from the adrenal medulla,
whereas the term of PGL is used for the extra-adrenal, usually catecholamine-
producing tumors arising from sympathetic paraganglia located in the thorax-
abdomen. The definition of head and neck PGL (hnPGL) is reserved for
noncatecholamine-producing tumors originating from parasympathetic para-
ganglia (carotid body, glomus jugulotympanic). The overall incidence of these
tumors is about 1 in 300,000.1
Clinical records suggest that approximately 10% of cases of PHEO/PGL and
up to 50% of hnPGL occur in a familial setting.2,3 There are four hereditary
syndromes that are associated with PHEO/PGL: multiple endocrine neoplasia
(MEN) Type 2A and 2B, neurofibromatosis (NF1) and von Hippel–Lindau syn-
drome (VHL); the genes involved are RET (OMIM 164761), NF1 (OMIM
162200), and VHL (OMIM 193300), respectively.
In addition, recent studies have shown that germline mutations in nuclear
genes coding for the subunits B, D, and C of the mitochondrial succinate
dehydrogenase complex II (SDH) are often associated with nonsyndromic,
familial as well as apparently sporadic, PHEO/PGL. A growing body of data
supports that the real prevalence of pathogenic germline mutations in these
genes among patients presenting with nonsyndromic PHEO/PGL is probably
much larger than supposed earlier on the basis of a positive family history for
the disease.
We have therefore performed molecular screening in a sample of Italian pa-
tients referring to hypertension clinics for sporadic and familial nonsyndromic
PHEO/PGL in order to evaluate the frequency of germline mutations in the
genes coding for the VHL, RET, and SDH (B, C, and D) in this particular
clinical setting.
PATIENTS AND METHODS
Patients
We have examined the medical records of patients referred to the hyper-
tension centers of the University of Brescia and the University of Turin in
the last 20 years and then selected those with PHEO/PGL. The diagnosis was
supported by clinical, biochemical (plasma and/or urinary catecholamines,
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chromogranin A), and imaging data (computed tomography, magnetic
resonance, 131I-metaiodbenzylguanidine or In-111 Pentreotide scintigraphy,
as needed). After exclusion of syndromic patients with MEN–2, von Hippel–
Lindau, or neurofibromatosis features, only familial and sporadic cases of iso-
lated PHEO/PGL were considered. Thus far, we have examined 45 probands,
35 with PHEO, 7 with PGL, and 3 with hnPGL. In this group of subjects
there were three probands with a positive family history (1 PHEO, 1 PGL, and
1 hnPGL patient).
After obtaining an informed written consent, germline DNA was extracted
from 10 mL of peripheral blood, using the DNA Isolation Kit for Mammalian
Blood (Roche Diagnostic, Mannheim, Germany) according to the manufac-
turer’s instructions.
Mutation Screening
DNA (200 ng) was amplified with intronic primers (TABLE 1) flanking the
eight exons of SDHB, four exons of the SDHD,4 six exons of SDHC, three
exons of VHL5 and exons 10, 11, 13, 14, 15, 16 of RET gene. Polymerase
chain reaction (PCR) conditions were as follows: 5 min of denaturation at
94◦C, then 38 cycles of denaturation (94◦C), annealing (see TABLE 1 for tem-
perature conditions), and polymerization (72◦C) for 30 sec, respectively. PCR
products were purified with Microcon 50 (Millipore, Billerica, MA) and se-
quenced using BigDye Terminator v1.1 Sequencing Kit (Applied Biosystems,
Foster City, CA). After a purification step performed with CentriSep Spin
Columns (Princeton Separations, Adelphia, NJ), the products were analyzed
on a 310 DNA Analyzer (Applied Biosystems).
RESULTS
No mutation in the examined RET gene exons was detected in our group of
patients.
Each of the three patients (1 PGL, 1 PHEO, and 1 hnPGL) with a positive
family history were carriers of genetic variants of potential pathogenic rele-
vance. The patient presenting with familial PGL (Patient 5, see TABLE 2) had
the mutation 688 C>G, corresponding to an arginine to glycine substitution
(R230G) in exon 7 of the SDHB gene; Patient 8 (PHEO) presented the mu-
tation 277G>T, G93C, in exon 1 of the VHL gene; and Patient 7 (hnPGL)
presented the mutation 348–351delGACT in exon 4 of the SDHD gene.
Of the six patients with apparently sporadic PGL four were carriers of ger-
minal sequence variants: one of them (Patient 2, 137G>A, R46Q, in exon 2 of
SDHB) has been previously described in association with PHEO/PGL.6 The
remaining three variants (Patient 1, 23C>T, S8F, in exon 1 of SDHB; Patient
6, 688C>G, R230G, in exon 7 of SDHB; and Patient 10, 242C>T, P81L, in
exon 1 of VHL) presented novel mutations to our knowledge.
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TABLE 1. Set of primers and annealing temperature for PCR amplification of the differ-
ent gene exons
Temp
(◦C)
SDHB
1F GGTCCTCAGTGGATGTAGGC 1R TCCTCCATCTCCCTGAGGCCTTG 61
2F TGGATATTGAATGCCTGCCT 2R GCCTTCCAAGGATGTGAAAA 63
3F ATTCCGAAGGTGACCTGAGA 3R CTCTATCAGCTTTGGCCAGC 63
4F CAGCAAGGAGGATCCAGAAG 4R ACAAATCCTGCCCTGAAAAA 63
5F CAGTGTCCAAGAAATGGGGT 5R TGAACGTTCCTCTCCAGAAT 63
6F GCACTGACCCCAAAGGTAAC 6R ATGGCAATGAAGGAAACCAG 63
7F CCAGAGCTTTGAGTTGAGCC 7R TGGTCCCTTTCCTTCTCAAA 63
8F AACCCCTATGGTTTTGAGGG 8R CTGCGGCAAGTAAAGGAACA 63
SDHD
1F GTTGGTGGATGACCTTGAGC 1R TGAGTCCTCACTTCCATCCC 60
2F TCAGTCCTGTTAAAGGAGAGGTTC 2R CCTGCTAAAGGCATGACCA 55
3F AAAGATGTGTGTTTCTCACA 3R CAGCAAACAAACTGAGCAGACA 55
4F GTATAGTCTTCTAATTTCACT 4R CAATTCTTCAAAGTATGAAGT 55
SDHC
1F CGTCACATGACACCCCCAAC 1R CTCCCAGTCCCACTGAA 60
2F AATCTATCCCTTCACCCCTA 2R ATCTCCAGACTTAGAAACTT 50
3F TCAAACGGTCATGGTTTTAT 3R CTCTGGCTCCAGAATCCTTC 55
4F ACTCTCTACTATGGTGTCAT 4R TGTGTAAAAACACATATACAT 50
5F AGCAGCTGTGACAAGCTACT 5R CTCCCTTCACAGAGAAAATG 55
6F CTGTTAATGTCCTATTTACT 6R CCAAGGAGATCTGAAAATACA 53
VHL
1F TGGTCTGGATCGCGGAGGGA 1R GACCGTGCTATCGTCCCTGC 63
2F GTGGCTCTTTAACAACCTTTGC 2R ACTTACCACAACAACCTTATC 55
3F TTCCTTGTACTGAGACCCTAGT 3R TCCTGTATCTAGATCAAGACTC 55
RET
10S GGAGGCTGAGTGGGCTACG 10R CTGGGAGGTGGTGGTGGTC 66,5
11S CTCTGGCGGTGCCAAGCCTC 11R GAAGGCAGCTGGGGAGGGCA 66,5
13S AACTTGGGCAAGGCGATGCA 13R AGAACAGGGCTGTATGGAGC 65
14S AAGACCCAAGCTGCCTGAC 14R GCTGGGTGCAGAGCCATAT 66
15S CCCCCGGCCCAGGTCTCAC 15R GCTCCACTAATCTTCGGTATCTTT 55
16S AGGGATAGGGCCTGGCCTTC 16R TAACCTCCACCCCAAGAGAG 55
In the two patients with sporadic hnPGL, genetic screening revealed one
previously unreported mutation in Patient 3: a 269G>A transversion, leading
to R90Q substitution, in exon 3 of SDHB.
The screening performed on 34 cases of apparently sporadic PHEO showed
the presence of sequence variants in eight patients. Two of them were positive
for mutations in the VHL gene: Patient 9, with 256C>G, P86A in exon 1
and Patient 11 with 561C>T, R167W in exon 3. Both mutations have been
previously described in association with PHEO.7,8 Patient 4 carried two distinct
SDHB variants: a 18A>C transversion, A6A, in exon 1, known as genetic
polymorphism9 and a 487T>C, S163P, in exon 5; such missense mutation has
been considered a polymorphic variant in a Spanish population,10 but we have
not found such variation in a series of 70 Italian controls (140 chromosomes).
160 ANNALS NEW YORK ACADEMY OF SCIENCES
T
A
B
L
E
2.
C
lin
ic
al
fe
at
ur
es
of
pa
ti
en
ts
ca
rr
yi
ng
se
qu
en
ce
va
ri
an
ts
in
SD
H
B
,S
D
H
D
an
d
V
H
L
ge
ne
s
C
li
ni
ca
l
S
cr
ee
ne
d
fe
at
ur
es
A
ge
at
re
la
tiv
es
/
M
ut
at
io
n
Pa
ti
en
t
tu
m
or
fi
rs
t
ca
rr
ie
rs
/
M
ut
at
io
n
ty
pe
nu
m
be
r
si
te
F
M
al
ig
na
nc
y
di
ag
no
si
s
U
C
S
ci
nt
ig
ra
ph
y
af
fe
ct
ed
re
fe
re
nc
e
S
D
H
B
23
T
>
C
S
8F
1
L
ef
tp
ar
a-
ad
re
na
lP
G
L
−
−
28
−
M
IB
G
+
3/
2/
0
N
ew
S
D
H
B
13
7G
>
A
,R
46
Q
2
R
ig
ht
pa
ra
-a
dr
en
al
P
G
L
−
−
45
+
n.
a.
5/
0
6
S
D
H
B
26
9G
>
A
,R
90
Q
3
B
il
at
er
al
ty
m
pa
ni
c
an
d
ca
ro
ti
d
hn
-P
G
L
−
−
33
−
n.
a.
3/
0
N
ew
S
D
H
B
48
7T
>
C
,S
16
3P
18
A
>
C
A
6A
4
R
ig
ht
ad
re
na
lP
H
E
O
−
−
17
+
M
IB
G
+
−
10
,9
S
D
H
B
82
2C
>
G
,R
23
0G
5
L
ef
tj
ux
ta
-a
dr
en
al
in
te
ra
or
to
ca
va
l
m
ul
ti
fo
ca
lP
G
L
+
+
9
+
M
IB
G
-O
C
T
+
16
/6
/1
N
ew
6
R
ig
ht
pa
ra
-a
or
ti
c
P
G
L
−
−
28
+
M
IB
G
+
29
/1
6/
2
S
D
H
D
34
8–
35
1d
el
G
A
C
T
7
C
ar
ot
id
gl
om
ou
s
hn
-P
G
L
+
L
oc
al
47
−
O
C
T
+
−
30
in
va
si
vi
ty
V
H
L
27
7G
>
T
G
93
C
8
A
dr
en
al
bi
la
te
ra
lP
H
E
O
+
−
31
+
n.
a.
1/
1/
1
24
V
H
L
25
6C
>
G
,P
86
A
9
A
dr
en
al
bi
la
te
ra
lP
H
E
O
−
−
9
+
M
IB
G
+
0
7
V
H
L
24
2C
>
T,
P
81
L
10
L
ef
tp
ar
a-
ad
re
na
lP
G
L
−
−
35
+
M
IB
G
+
0
N
ew
V
H
L
56
1C
>
T,
R
16
7W
11
A
dr
en
al
bi
la
te
ra
lP
H
E
O
−
−
28
+
M
IB
G
+
0
8
S
D
H
D
14
9A
>
G
,H
50
R
12
R
ig
ht
ad
re
na
lP
H
E
O
−
−
65
+
M
IB
G
+
0
11
13
P
H
E
O
−
−
n.
a.
+
n.
a.
0
S
D
H
D
20
4C
>
T,
S
68
S
34
G
>
A
,G
12
S
14
L
ef
ta
dr
en
al
P
H
E
O
−
−
54
+
n.
a.
0
12
S
D
H
B
IV
S
1–
11
1G
>
A
15
R
ig
ht
ad
re
na
lP
H
E
O
−
−
45
+
M
IB
G
+
0
4
S
D
H
B
IV
S
2
+
35
G
>
A
IV
S
4
+
60
T
>
C
16
P
H
E
O
−
−
40
+
n.
a.
0
9
O
C
T
=
O
ct
re
os
ca
n;
U
C
=
ur
in
ar
y
ca
te
ch
ol
am
in
e;
n.
a.
=
no
ta
va
il
ab
le
;F
=
fa
m
il
ia
ri
ty
;−
=
ne
ga
tiv
e;
+
=
po
si
tiv
e;
F
=
fa
m
il
ia
l.
CASTELLANO et al.: GENETIC MUTATION SCREENING 161
We have found additional known polymorphisms in five other patients with
sporadic PHEO: two of them (Patients 12 and 13) presented the nonsynony-
mous 149A>G substitution, H50R, in exon 3 of SDHD11 and Patient 14
was a carrier of two polymorphisms,12 34G>A, G12S and 204C>T, S68S
in SDHD exon 1 and 3, respectively. Three additional intronic polymorphisms
of the SDHB gene were found in Patient 15 (IVS1–111 G>A) and Patient
16 (IVS2 + 35 G>A and IVS4 + 60T>C).
We have further investigated the three missense mutations of SDHB gene
(S8F, R90Q, and R230G), which have not been described before, in order to
define their clinical relevance better. First, we have not found similar gene
variants in a cohort of 70 healthy subjects. We have then considered whether
the amino acids involved (S8, R90, R230) are conserved among different verte-
brate and invertebrate species. As shown in FIGURE 1, positions S8 and S163 are
conserved in different mammalian species (Rattus norvegicus, Mus musculus,
Pan troglodytes, Canis familiaris), while positions R90 and R230 are iden-
tical both in mammalian and invertebrate species. We further evaluate loss
of heterozygosis (LOH) in the available tumoral tissues; we were able to ex-
FIGURE 1. Conservation of amino acid position S8, R90, S163, and R230 of SDHB
protein among different species.
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tract DNA from an abdominal, catecholamine-producing PGL from Patient
6 (R230G mutation) and amplify them with a set of primers surrounding mi-
crosatellites D1S199, D1S2644, D1S2697, and D1S507: the results (data not
shown) confirmed somatic LOH. Finally we considered PHEO/PGL pene-
trance among relatives of probands carrying the same mutation. In particular,
we have been able to examine two large kindreds from Patient 5 (familial PGL)
and Patient 6 (sporadic PGL), both carriers of the R230G mutation in SDHB
gene: among 22 carriers of such mutation found in the two kindreds, three
more subjects were affected by PHEO/PGL.
DISCUSSION
In the present screening of an Italian sample of PHEO/PGL patients repre-
sentative of the specialized hypertensive clinical setting, we have been able
to find 17 sequence variants in genes potentially involved in PHEO/PGL
pathogenesis. Of these, five (SDHB R46Q, SDHD 348-351 delGACT, VHL
G93C, P86A, and R167W) have been previously described in association with
PHEO/PGL, while three (SDHB S8F, R90Q, and R230G and VHL P81L) are
novel mutations that presumably play a causative role. In addition, we have
found eight known genetic polymorphisms. Accordingly, the overall preva-
lence of clinically significant mutations is 10 of 45 patients (22%), with rel-
ative contribution of 5 of 45 (11%), 4 of 45 (9%), and 1 of 45 (2%) for
SDHB, VHL, and SDHD genes, respectively. If we limit our consideration to
PHEO/PGLs presenting in a familial setting, the prevalence of pathogenically
relevant mutations is 100% (3 of 3), but in sporadic forms the frequency of
mutation is also very high, in substantial agreement with the literature, show-
ing similar data in a large collection of patients with sporadic PHEO/PGL
(TABLE 3).
In our sample no patient presented mutations of RET or SDHC genes. As a
matter of fact, we preliminarily excluded PHEO/PGL occurring in syndromic
form, and PHEO is almost never the first clinical manifestation of a MEN2
syndrome; on the other hand, only eight cases of SDHC-associated PGL have
been reported thus far.
TABLE 3. Occult germline mutations in sporadic nonfamilial phaeochromocytomas
No. of Subjects with Present
Gene patients mutations Percent Reference data (%)
RET 712 22 3.1 (0–21.4) 16–26 0
VHL 586 41 7.0 (0–20) 18, 20, 23, 24–27 7.9
SDHB 536 39 7.3 (4.9–14.3) 25, 26, 28, 29 12.5
SDHD 561 27 4.8 (0–8) 25, 26, 28–30 0
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It should also be noted that the prevalence of SDHD mutations is lower than
previously reported, but this may be at least in part due to the small number of
hnPGLs included in our samples, which are more frequently associated with
SDHD mutations.
From these data and previous evidence from the literature, we may argue
that the most cost-effective mutation screening strategy in the setting of hyper-
tensive patients with nonsyndromic PHEO is probably the sequential analysis
of VHL, SDHB, and SDHD, whereas in PGL the sequence should be SDHB,
SDHD, VHL, and SDHC.
We have been able to perform an extended pedigree analysis only in two
kindreds, both carrying the novel SDHB R230G mutation. Notably, only 5 of
22 mutation carriers had a diagnosis of PHE/PGL (two subjects in proband
6 family and three subjects in proband 5 family). None of the remaining 17
carriers, clinically asymptomatic, showed evidence of the disease on thorough
biochemical and imaging investigation.
Although our mutation screening by direct bidirectional sequencing is very
sensitive, we cannot exclude the occurrence of other mutations in intronic or,
regulatory regions, large deletions of the entire gene,13 or exon skipping pro-
moted by Alu intronic sequence, as recently reported by various authors.14,15
Southern blot or RNA analysis (RT-PCR or Northern blot) could give us more
complete results.
In conclusion, the present findings in an Italian cohort of PHEO/PGL
patients recruited through hypertension clinic facilities suggest that genetic
screening for mutations of candidate genes (at least SDHB, VHL, and SDHD)
is indicated not only in familial, but also in sporadic forms, given the relatively
high prevalence of pathogenically relevant mutations. However, a more precise
characterization of the functional relevance of any observed sequence variant
and of other genetic and environmental determinants of neoplastic transfor-
mation is essential in order to plan appropriate protocols for family screening
and follow-up.
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